Epstein-Barr virus-driven gene therapy for EBV-related lymphomas - PubMed

Affiliations

• PMID: 8946840
• DOI: 10.1038/nm1296-1379

Epstein-Barr virus-driven gene therapy for EBV-related lymphomas

M Franken et al. Nat Med. 1996 Dec.

Abstract

Genetic alterations in malignant tissues are potential targets for gene-based cancer therapies. Alternatively, aberrant expression of certain specific genes associated with malignant transformation may be envisioned to enhance the expression of chemosensitizing drugs. Epstein-Barr virus (EBV)-related B-cell lymphomas are fatal complications of immunosuppression due to AIDS, organ transplantation or congenital immune abnormalities. The malignant cells latently infected with EBV typically express the transcription factor EBNA2 as one of nine latent viral genes. We tested whether an EBNA2-responsive EBV promoter may selectively target EBV-related lymphoma cells by virus-regulated expression of a suicide gene. Using the BamC promoter driving a hygromycin-thymidine kinase fusion gene or controls, we demonstrated that sensitivity to ganciclovir was selectively enhanced in cells expressing EBNA2. Further, there was complete macroscopic regression of established B-cell lymphomas in mice with severe combined immunodeficiency disease (SCID mice) treated with a single course of ganciclovir. These data provide in vitro and in vivo support for a model of exploiting the molecular basis of tumor development to enhance the specificity of gene therapy.

Similar articles

• Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase.

  Rogers RP, Ge JQ, Holley-Guthrie E, Hoganson DK, Comstock KE, Olsen JC, Kenney S. Rogers RP, et al. Hum Gene Ther. 1996 Dec 1;7(18):2235-45. doi: 10.1089/hum.1996.7.18-2235. Hum Gene Ther. 1996. PMID: 8953314

• Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells.

  Wang F, Marchini A, Kieff E. Wang F, et al. J Virol. 1991 Apr;65(4):1701-9. doi: 10.1128/JVI.65.4.1701-1709.1991. J Virol. 1991. PMID: 1848303 Free PMC article.

• Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies.

  Faller DV, Mentzer SJ, Perrine SP. Faller DV, et al. Curr Opin Oncol. 2001 Sep;13(5):360-7. doi: 10.1097/00001622-200109000-00008. Curr Opin Oncol. 2001. PMID: 11555713 Review.

• Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.

  Westphal EM, Mauser A, Swenson J, Davis MG, Talarico CL, Kenney SC. Westphal EM, et al. Cancer Res. 1999 Apr 1;59(7):1485-91. Cancer Res. 1999. PMID: 10197618

• Epstein-Barr virus vectors for gene therapy.

  Komaki S, Vos JM. Komaki S, et al. Adv Virus Res. 2000;55:453-62. doi: 10.1016/s0065-3527(00)55012-x. Adv Virus Res. 2000. PMID: 11050951 Review. No abstract available.

Cited by

• The expression and function of Epstein-Barr virus encoded latent genes.

  Young LS, Dawson CW, Eliopoulos AG. Young LS, et al. Mol Pathol. 2000 Oct;53(5):238-47. doi: 10.1136/mp.53.5.238. Mol Pathol. 2000. PMID: 11091847 Free PMC article. Review.

• EBNA-1, a bifunctional transcriptional activator.

  Kennedy G, Sugden B. Kennedy G, et al. Mol Cell Biol. 2003 Oct;23(19):6901-8. doi: 10.1128/MCB.23.19.6901-6908.2003. Mol Cell Biol. 2003. PMID: 12972608 Free PMC article.

• Humanized mouse models of epstein-barr virus infection and associated diseases.

  Fujiwara S, Matsuda G, Imadome K. Fujiwara S, et al. Pathogens. 2013 Mar 14;2(1):153-76. doi: 10.3390/pathogens2010153. Pathogens. 2013. PMID: 25436886 Free PMC article. Review.

• Fas and mutant estrogen receptor chimeric gene: a novel suicide vector for tamoxifen-inducible apoptosis.

  Kodaira H, Kume A, Ogasawara Y, Urabe M, Kitano K, Kakizuka A, Ozawa K. Kodaira H, et al. Jpn J Cancer Res. 1998 Jul;89(7):741-7. doi: 10.1111/j.1349-7006.1998.tb03279.x. Jpn J Cancer Res. 1998. PMID: 9738981 Free PMC article.

• Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells.

  Von Seggern DJ, Huang S, Fleck SK, Stevenson SC, Nemerow GR. Von Seggern DJ, et al. J Virol. 2000 Jan;74(1):354-62. doi: 10.1128/jvi.74.1.354-362.2000. J Virol. 2000. PMID: 10590124 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information